Keywords
clinic
treatment
How to Cite
Abstract
Antiphospholipid syndrome (APS) is characterized by hypercoagulability, manifested by venous and /or arterial thrombosis, increased maternal and fetal mortality and morbidity, and serological abnormalities mediated by antiphospholipid antibodies. Of these, the best known are lupus anticoagulant (AL), anticardiolipin (aCL) and antiB2 glycoprotein i. This is an observational, descriptive study of a case series of patients with APS from a part of the Paraguayan population. in our population (n=25) we have 92% females and average age was 37,8 years. Deep venous thrombosis (DvT) and ischemic cerebrovascular accidents (CvA) were the predominant clinical manifestations. Secondary APS was present in 84% (21/25) of patients, most of them (70%) corresponding to SLE. Mortality was 8%.References
(1) Khamashta M, Taraborelli M, Sciascia S, Tincani A. Antiphospholipid syndrome. Best practice & research Clinical rheumatology. 2016;30(1):133-48.
(2) Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows. Nature reviews Rheumatology. 2015;11(10):586-96.
(3) Cervera R, Boffa MC, Khamashta MA, Hughes GR. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus. 2009;18(10):889-93.
(4) Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis care & research. 2013;65(11):1869-73.
(5) Cervera R. Antiphospholipid syndrome. Thrombosis research. 2017;151 Suppl 1:S43-s7.
(6) Alba P, Cuadrado MJ, Khamashta M. Manifestaciones clínicas del síndrome antifosfolípido. in: Battagliotti CA BM, Pons-Estel BA, Carreras LO, editor. Síndrome Antifosfolipídico Actualización clínica y terapéutica2002. p. 45-59.
(7) Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. The New England journal of medicine. 1995;332(15):993-7.
(8) Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. international consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309-11.
(9) Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. international consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of thrombosis and haemostasis: JTH. 2006;4(2):295-306.
(10) Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2007;66(7):927-30.
(11) Lockshin MD, Sammaritano LR, Schwartzman S. validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum. 2000;43(2):440-3.